#United States #Board of Directors #Alameda #Penumbra Inc #Don Kassing

Penumbra, Inc. Announces Don Kassing's Retirement from the Board

In a significant transition, Penumbra, Inc. (NYSE: PEN), recognized globally as a leader in thrombectomy solutions, revealed the upcoming retirement of Don Kassing from its Board of Directors. After an impressive 17 years with the company, Kassing will step down effective April 1, 2025. His ongoing contributions to the board have been profound, particularly in guiding the company's strategic growth and navigating complex challenges.

Don Kassing joined the board in 2008, and his leadership as Presiding Director since 2015 has been valuable to Penumbra. Adam Elsesser, the Board Chair and CEO of Penumbra, expressed gratitude for Kassing’s stewardship throughout the company’s phases of expansion. “We are thankful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth,” Elsesser stated. Kassing's commitment to advancing Penumbra's mission of improving patient outcomes has been steadfast.

Kassing's robust background extends beyond his board role. He is the President Emeritus of San Jose State University, having served as President from 2004 to 2008 and again as Interim President from 2010 to 2011. His prior administrative roles include Vice President of Administration and Finance and Chief Financial Officer from 1993 to 2004. Before his extensive career in academia, Kassing garnered nearly two decades in various sectors, including significant tenures in merchandising, marketing, and corporate finance. His experience at firms like General Motors Corporation and Caleres, Inc. has equipped him with the corporate acumen essential for navigating the intricacies of corporate governance and strategy.

Kassing holds a Bachelor of Arts and a Master of Business Administration from Saint Louis University. His qualifications and professional journey vividly illustrate his ability to lead a board through the evolving landscape of the healthcare sector.

About Penumbra, Inc.

Penumbra, Inc. leads the way in the development of innovative technologies for critical medical conditions, primarily focusing on thromboembolic challenges such as ischemic strokes and acute limb ischemia. Their advanced solutions, including the computer-assisted vacuum thrombectomy (CAVT), allow for safe, rapid, and effective removal of blood clots across the human body.

With operations spanning over 100 countries, Penumbra is dedicated to enhancing healthcare providers’ capabilities to provide quality patient care. The company’s commitment to innovation and patient-centered outcomes manifests in its array of advanced medical technologies.

For ongoing updates and further information about Penumbra, visit their official website at www.penumbrainc.com and follow them on social platforms including Instagram, LinkedIn, and X for the latest news and innovations.

Kassing's departure marks a noteworthy moment for Penumbra, prompting reflection on the impactful leadership that has ushered the company through years of growth and development into a robust player in the medical technology field. As the board prepares for this transition, the future of Penumbra looks promising under the collective guidance of its remaining directors and Garcia, who continues to see immense potential in their trajectory for years to come.